IRIS
MARABOTTO, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.399
NA - Nord America 2.267
AS - Asia 1.935
Continente sconosciuto - Info sul continente non disponibili 515
SA - Sud America 155
AF - Africa 37
OC - Oceania 7
Totale 16.315
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.023
US - Stati Uniti d'America 2.104
SG - Singapore 619
CN - Cina 464
BD - Bangladesh 357
VN - Vietnam 292
FR - Francia 133
BR - Brasile 87
CA - Canada 81
HK - Hong Kong 61
FI - Finlandia 56
GB - Regno Unito 42
DE - Germania 38
IN - India 36
JP - Giappone 29
AR - Argentina 26
MX - Messico 25
NL - Olanda 17
JM - Giamaica 12
ES - Italia 11
IQ - Iraq 11
UA - Ucraina 11
CL - Cile 10
CO - Colombia 10
EC - Ecuador 10
CR - Costa Rica 9
GT - Guatemala 9
ID - Indonesia 9
PH - Filippine 9
RU - Federazione Russa 9
IE - Irlanda 8
CH - Svizzera 7
JO - Giordania 7
NI - Nicaragua 7
SE - Svezia 7
PL - Polonia 6
VE - Venezuela 6
ZA - Sudafrica 6
HN - Honduras 5
KE - Kenya 5
SA - Arabia Saudita 5
TR - Turchia 5
AT - Austria 4
AU - Australia 4
AZ - Azerbaigian 4
EG - Egitto 4
LT - Lituania 4
NP - Nepal 4
RS - Serbia 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
BA - Bosnia-Erzegovina 3
BZ - Belize 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
MA - Marocco 3
MY - Malesia 3
PE - Perù 3
PR - Porto Rico 3
PT - Portogallo 3
SN - Senegal 3
DZ - Algeria 2
FJ - Figi 2
IL - Israele 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
PK - Pakistan 2
PY - Paraguay 2
RO - Romania 2
SI - Slovenia 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GP - Guadalupe 1
LC - Santa Lucia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
NC - Nuova Caledonia 1
SC - Seychelles 1
SV - El Salvador 1
TG - Togo 1
UG - Uganda 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 15.802
Salva come PNG Salva come JPEG
Città #
Genova 5.006
Genoa 3.926
Vado Ligure 897
Rapallo 830
San Jose 367
Ashburn 326
Singapore 261
Lauterbourg 116
New York 114
Council Bluffs 113
Beijing 89
Ho Chi Minh City 84
Hanoi 74
Los Angeles 70
Hong Kong 59
Santa Clara 47
Helsinki 45
Chicago 40
Dallas 40
Milan 36
Rome 34
Boardman 33
Buffalo 28
Orem 28
Tokyo 27
Toronto 27
Frankfurt am Main 26
Bordighera 21
Naples 21
San Francisco 20
Phoenix 19
Atlanta 18
Montreal 18
Mexico City 17
Da Nang 15
Brooklyn 13
Philadelphia 13
Bologna 11
Chennai 11
Lappeenranta 11
St Louis 11
Haiphong 10
Mumbai 10
São Paulo 10
Amsterdam 9
Dublin 9
Florence 9
Seattle 9
Charleston 8
Denver 8
Guatemala City 8
Hamilton 8
London 8
San José 8
Tianjin 8
Amman 7
Charlotte 7
Kingston 7
Kyiv 7
Las Vegas 7
Manchester 7
Memphis 7
Oklahoma City 7
Orlando 7
Palermo 7
Poplar 7
Shanghai 7
Stockholm 7
Stockton 7
Turin 7
Zurich 7
Boston 6
Brescia 6
Columbus 6
Houston 6
Medford 6
Miami 6
Ocala 6
Pittsburgh 6
Princeton 6
Queens 6
Warsaw 6
Buenos Aires 5
Cardiff 5
Des Moines 5
Greensboro 5
Guangzhou 5
Jacksonville 5
Kansas City 5
Newark 5
Padua 5
Paris 5
Strafford 5
Baghdad 4
Bari 4
Belgrade 4
Cagliari 4
Concepción 4
Detroit 4
Guayaquil 4
Totale 13.345
Salva come PNG Salva come JPEG
Nome #
Proton pump inhibitors: use and misuse in the clinical setting 250
Italian guidelines for the diagnosis and management of gastro-esophageal reflux disease: Joint consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), and General Medicine (SIMG) 229
Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers 223
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 223
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 216
Advancements in the use of manometry and impedance testing for esophageal functional disorders 210
Measurement of oro-caecal transit time by magnetic resonance imaging. 209
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 206
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 204
A safety review of proton pump inhibitors to treat acid-related digestive diseases 202
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 200
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 198
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. 189
Drugs for improving esophageal mucosa defense: Where are we now and where are we going? 189
The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. 185
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 181
Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease 176
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 173
Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. 171
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 171
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 169
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 168
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 165
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 162
The appropriate use of proton-pump inhibitors 162
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 161
Microscopic Esophagitis is More Frequent in Patients With pH-Positive Non-Erosive Reflux Disease and Hypersensitive Esophagus Than in Those With Functional Heartburn: A Study Using Impedance-pH and Optical Microscopy. 159
Optimal management of constipation associated with irritable bowel syndrome. 158
Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602]. 157
Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity 156
The natural history of gastro-esophageal reflux disease: A comprehensive review 155
Epidemiology and natural history of gastroesophageal reflux disease 153
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 148
Overweight is a risk factor for both erosive and non-erosive reflux disease. 146
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. 145
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 143
Expression of Epidermal Growth Factor receptor (EGFR) in Systemic Sclerosis patients (SSc) and Gastro-oesophageal Reflux Disease (GORD) 141
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 140
Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD 139
Relevance of measuring substances in bronchoalveolar lavage fluid for detecting aspiration-associated extraesophageal reflux disease 139
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 139
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 138
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 137
Pathophysiological studies are mandatory to understand the benefit of proton pump inhibitors in patients with idiopathic pulmonary fibrosis 137
Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn 136
Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis 135
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 131
Esophageal motility abnormalities in gastroesophageal reflux disease 131
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 130
Can High-Frequency Intraoral Ultrasound Predict Histological Risk Factors in Oral Squamous Cell Carcinoma? A Preliminary Experience 128
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 127
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 127
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 127
CLINICAL AND ENDOSCOPIC-HISTOLOGICAL FEATURES OF MULTIFOCAL AND CORPUS-RESTRICTED ATROPHIC GASTRITIS PATIENTS WITH NON-CARDIA GASTRIC CANCER OR DYSPLASIA: A MULTICENTER, CROSS-SECTIONAL STUDY 125
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 125
Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia 122
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 122
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 119
Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients with Eosinophilic Esophagitis 119
Diabetes Medications and Risk of Hepatocellular Carcinoma 119
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 118
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 115
Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance 113
Esophageal motor disorders across ages: A retrospective multicentric analysis 112
Effects of bariatric surgery on the esophagus 112
Updates in the field of non-esophageal gastroesophageal reflux disorder 112
Vonoprazan fumarate for the management of acid-related diseases 112
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 109
Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis. 104
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 104
The Lyon Consensus: Does it differ from the previous ones? 104
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 104
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis–Current Treatment and Monitoring 98
A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring 98
Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high‐resolution manometry studies 97
Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications 97
Pharmacotherapies in eosinophilic esophagitis: state of the art 97
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 96
Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis 95
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 95
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication 95
Expression of Epidermal Growth Factor Receptor in patients with gastro-oesophageal reflux disease and in those with Systemic Sclerosis 94
Nonacid Reflux Is Able to Determine Microscopic Esophagitis in Non-Erosive Reflux Disease (NERD) Patients. 92
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis 92
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 90
Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach 88
Prevention Strategies for Esophageal Cancer—An Expert Review 86
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 86
Evaluation of the pathophysiological association between the GERD and OSAS: Esophageal pH-monitoring results beyond Lyon criteria 85
Improving the Diagnostic Yield of High-Resolution Esophageal Manometry for GERD: The “Straight Leg-Raise” International Study 85
Food Intolerances, Food Allergies and IBS: Lights and Shadows 85
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 84
Clopidogrel-Induced Eosinophilic Colitis 83
The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions 83
null 83
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission 82
Diagnostic delay in achalasia 81
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease 81
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 81
Diagnostic delay and misdiagnosis in eosinophilic oesophagitis 80
Totale 13.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.924
article - articoli 55.397
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 527
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.848
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.036 102 27 67 95 33 104 32 229 66 121 36 124
2022/20231.013 105 100 19 87 177 131 6 85 177 5 110 11
2023/2024726 25 74 8 100 54 124 61 21 32 36 64 127
2024/20252.467 136 138 116 164 266 295 200 398 117 96 272 269
2025/20265.986 555 178 492 522 567 422 756 278 456 649 444 667
2026/2027860 860 0 0 0 0 0 0 0 0 0 0 0
Totale 16.315